Philip Kantoff

Philip Kantoff is a medical oncologist who spent three decades shaping how the world treats prostate cancer, then walked away from running medicine at one of the country's largest cancer hospitals to start a company. As co-founder and CEO of Convergent Therapeutics in Cambridge, Massachusetts, he is developing CONV01-alpha, an alpha-emitting radioantibody that hunts down prostate tumor cells and irradiates them at close range. He has published more than 500 papers, been cited over 85,000 times, mentored a generation of oncology leaders, and at an age when most peers retire, raised $90 million in Series A funding to bring a new class of cancer therapy into the clinic.